Scarica l'app Stockscreener
32.96
0.24%
-0.08
Dopo l'orario di chiusura:
32.94
-0.02
-0.06%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$33.04
Aprire:
$33.16
Volume 24 ore:
554.56K
Relative Volume:
0.66
Capitalizzazione di mercato:
$13.99B
Reddito:
$5.97B
Utile/perdita netta:
$493.76M
Rapporto P/E:
29.38
EPS:
1.122
Flusso di cassa netto:
$799.66M
1 W Prestazione:
-3.93%
1M Prestazione:
-8.90%
6M Prestazione:
-12.76%
1 anno Prestazione:
+16.84%
Intervallo 1D:
$32.90
$33.23
Intervallo di 1 settimana:
$32.52
$34.10
Portata 52W:
$23.91
$38.79
Smith Nephew Plc Adr Stock (SNN) Company Profile
Nome
Smith Nephew Plc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare SNN vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNN
Smith Nephew Plc Adr
|
32.96 | 13.99B | 5.97B | 493.76M | 799.66M | 1.122 |
|
ABT
Abbott Laboratories
|
108.03 | 187.72B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
336.77 | 128.88B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
87.14 | 111.88B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.13 | 102.58B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
81.81 | 47.52B | 6.07B | 1.06B | 1.34B | 1.8063 |
Smith Nephew Plc Adr Stock (SNN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-15 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-14 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2025-04-25 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-03-12 | Downgrade | UBS | Buy → Neutral |
| 2024-11-06 | Downgrade | Berenberg | Buy → Hold |
| 2024-11-01 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-07-24 | Iniziato | Deutsche Bank | Buy |
| 2024-06-05 | Aggiornamento | UBS | Neutral → Buy |
| 2023-11-28 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2023-11-03 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-10-31 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2023-10-13 | Iniziato | Stifel | Hold |
| 2023-08-08 | Aggiornamento | UBS | Sell → Neutral |
| 2023-04-27 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-04-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-12 | Iniziato | Citigroup | Buy |
| 2022-11-28 | Downgrade | UBS | Neutral → Sell |
| 2022-10-18 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-07-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-03-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-03-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-03-04 | Aggiornamento | Redburn | Sell → Neutral |
| 2021-06-09 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-18 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2020-12-01 | Iniziato | Barclays | Overweight |
| 2020-07-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-04 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-14 | Downgrade | Citigroup | Buy → Neutral |
| 2019-11-21 | Iniziato | Citigroup | Buy |
| 2019-11-12 | Iniziato | Bernstein | Outperform |
| 2019-07-23 | Aggiornamento | Berenberg | Hold → Buy |
| 2019-02-08 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2019-01-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-11-01 | Reiterato | Canaccord Genuity | Buy |
| 2018-01-25 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-12-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2017-10-11 | Iniziato | Canaccord Genuity | Buy |
| 2017-02-27 | Downgrade | Goldman | Buy → Neutral |
| 2017-01-19 | Iniziato | HSBC Securities | Hold |
| 2016-12-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2016-10-06 | Downgrade | Berenberg | Buy → Hold |
| 2016-02-26 | Iniziato | Cantor Fitzgerald | Hold |
Mostra tutto
Smith Nephew Plc Adr Borsa (SNN) Ultime notizie
Smith+Nephew launches next-generation ALLEVYN COMPLETE CARE Foam Dressingdesigned for high performance in wound management and pressure injury prevention - Finviz
NVIDIA Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Smith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026 - GlobeNewswire Inc.
Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026 - Sahm
Smith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026 - Sahm
Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026 - Finviz
Smith & Nephew FTSE Healthcare Market Presence and Operational Developments - Kalkine Media
Smith+Nephew signs exclusive US distribution agreement with RMR Ortho for patented technology that provides a unique dynamic compression nitinol fixation option (A'TOMIC) to our surgeons - Finviz
Smith+Nephew signs exclusive US distribution agreement with RMR Ortho for patented technology that provides a unique dynamic compression nitinol fixation option (A'TOMIC™) to our surgeons - Sahm
Smith+Nephew signs distribution agreement with SI-BONE - Finviz
Factory Mutual Insurance Co. Buys New Stake in Smith & Nephew SNATS, Inc. $SNN - Defense World
Jim Cramer on Smith & Nephew: "This Group, I Do Not Like" - Finviz
Smith+Nephew completes acquisition of Integrity Orthopaedics; establishes unrivalled portfolio for shoulder repair - Finviz
The Truth About Smith & Nephew plc: Why This ‘Boring’ Med-Tech Stock Might Be Your Sneaky Power - AD HOC NEWS
Smith & Nephew ADR trying to close in on key technical benchmark - MSN
The Truth About Smith & Nephew plc (ADR): Wall Street Sleeper Stock or Total Snooze? - AD HOC NEWS
Smith & Nephew plc (ADR): Quiet Charts, Cautious Optimism – Is SNN a Sleeper in Medtech? - AD HOC NEWS
Smith & Nephew (SN, SNN) Stock Outlook for December 2025: Q3 Setback, $500m Buyback and What Comes Next - ts2.tech
Smith and Nephew (LON:SN) positioned across FTSE 100 Today healthcare landscape - Kalkine Media
FTSE 100 today: Pound lower; Magnum debuts, Smith & Nephew sets new goals - Investing.com
Smith & Nephew Unveils RISE Blueprint for a Stronger Future - Kalkine Media
Smith+Nephew sets ambitious growth targets through 2028 - Investing.com
Smith & Nephew (SNN) Stock Forecast 2026: Q3 2025 Results, $500m Buyback and New Board Signals - TechStock²
Smith & Nephew PLC (NYSE:SNN): A Value Investment in Medical Devices - Chartmill
[6-K] SMITH & NEPHEW PLC Current Report (Foreign Issuer) | SNN SEC FilingForm 6-K - Stock Titan
Smith & Nephew PlcDirector/PDMR Shareholding - Research Tree
REGSmith & Nephew PlcDirector/PDMR Shareholding - TradingView
Smith & Nephew stock initiated with Buy rating at Kepler Cheuvreux - Investing.com
Shell Stock Price Today (12 Nov 2025): SHEL ADR edges lower as oil slides; London closes at 2,909p amid fresh buyback and Volta Media sale - ts2.tech
Smith+Nephew shares tumble as Q3 sales miss expectations - Investing.com
Analysts Set Smith & Nephew SNATS, Inc. (NYSE:SNN) Price Target at $36.75 - Defense World
Smith+Nephew comparative study1 shows PICO◊ sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWT - Sahm
Smith Nephew Plc Adr Azioni (SNN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.66%
1.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):